The growth in the historic period can be attributed to high global prevalence of hepatitis b infection, early adoption of recombinant vaccines, government led immunization programs, increasing healthcare awareness, success of childhood vaccination initiatives.
The growth in the forecast period can be attributed to expansion of adult vaccination programs, rising focus on healthcare worker safety, growing vaccination coverage in emerging markets, stronger public health funding, increasing emphasis on preventive healthcare. Major trends in the forecast period include expansion of universal hepatitis b vaccination, focus on preventive immunization programs, rising demand for adult and booster vaccines, strengthening of public health vaccination policies, increased coverage in high risk populations.
The increasing prevalence of hepatitis B virus (HBV) infection is expected to drive the growth of the engerix-B market in the coming years. Hepatitis B is a serious liver condition caused by HBV, which can lead to chronic disease, liver damage, and a higher risk of liver cancer. Factors contributing to the spread of HBV include unprotected sexual contact, blood-to-blood exposure, lack of vaccination, and weakened immunity. Engerix-B contains a non-infectious version of the HBV surface antigen, which stimulates the immune system to provide protection against the virus. It offers long-lasting immunity, reducing the risk of infection and its complications. For example, in April 2024, the World Health Organization reported that global health strategies aim to ensure that 80% of individuals living with chronic hepatitis B and C receive treatment by 2030. Therefore, the rising prevalence of HBV infection is supporting the growth of the engerix-B market.
Rising travel and migration are also expected to propel the growth of the engerix-B market. Travel and migration involve people moving across regions or countries for reasons such as leisure, work, education, family reunification, or environmental factors. These movements increase exposure to high-risk areas for HBV infection. Engerix-B provides essential protection for travelers and migrants by reducing the risk of infection through contaminated blood, needles, or bodily fluids, ensuring safer movement between regions. For instance, in May 2024, the Office for National Statistics reported that the UK recorded 38 million visits in 2023, an increase of 6.7 million compared to 2022, while outbound trips by UK residents rose from 71 million in 2022 to 86.2 million in 2023. Consequently, increasing travel and migration are driving the growth of the engerix-B market.
Rising healthcare expenditure is another key factor supporting the growth of the engerix-B market. Healthcare expenditure encompasses all spending on medical services, treatments, and products across both public and private sectors. Factors such as an aging population and higher prevalence of chronic and age-related conditions contribute to increased healthcare costs. Greater healthcare spending enhances the accessibility of vaccines like Engerix-B by funding vaccination programs, strengthening healthcare infrastructure, and ensuring affordability, which reduces long-term costs associated with treating hepatitis B and its complications. For example, in May 2024, the Office for National Statistics reported that total healthcare expenditure in the UK increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is expected to drive the growth of the engerix-B market.
Major companies operating in the engerix-b market are GlaxoSmithKline plc.
North America was the largest region in the engerix-B market in 2025. The regions covered in the engerix-b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the engerix-b market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the engerix-b market by affecting vaccine raw material sourcing, packaging components, and international distribution logistics. These impacts are most visible in public vaccination programs and healthcare institutions in regions dependent on imported vaccines. Increased costs may strain government procurement budgets and slow rollout schedules. However, tariffs are also encouraging domestic vaccine manufacturing and regional production hubs. This supports long term vaccine supply security and self sufficiency.
The engerix-b market research report is one of a series of new reports that provides engerix-b market statistics, including engerix-b industry global market size, regional shares, competitors with a engerix-b market share, detailed engerix-b market segments, market trends and opportunities, and any further data you may need to thrive in the engerix-b industry. This engerix-b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Engerix-B is a vaccine that protects against hepatitis B, a serious liver infection caused by the hepatitis B virus (HBV). It contains hepatitis B surface antigen (HBsAg), a viral protein that stimulates the immune system to produce antibodies without causing the disease.
The primary indications for Engerix-B include prevention of hepatitis B virus (HBV) infection, chronic hepatitis B prevention, protection for healthcare workers and high-risk populations, and post-exposure prophylaxis. The vaccine works by triggering the immune system to generate antibodies, providing long-term immunity for at-risk individuals. It is distributed through hospitals, clinics, vaccination centers, and pharmacies, and is used by private healthcare providers, long-term care facilities, and educational institutions.
The engerix-B market consists of sales of adjuvants, buffering agents, and excipients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of adult vaccination programs, rising focus on healthcare worker safety, growing vaccination coverage in emerging markets, stronger public health funding, increasing emphasis on preventive healthcare. Major trends in the forecast period include expansion of universal hepatitis b vaccination, focus on preventive immunization programs, rising demand for adult and booster vaccines, strengthening of public health vaccination policies, increased coverage in high risk populations.
The increasing prevalence of hepatitis B virus (HBV) infection is expected to drive the growth of the engerix-B market in the coming years. Hepatitis B is a serious liver condition caused by HBV, which can lead to chronic disease, liver damage, and a higher risk of liver cancer. Factors contributing to the spread of HBV include unprotected sexual contact, blood-to-blood exposure, lack of vaccination, and weakened immunity. Engerix-B contains a non-infectious version of the HBV surface antigen, which stimulates the immune system to provide protection against the virus. It offers long-lasting immunity, reducing the risk of infection and its complications. For example, in April 2024, the World Health Organization reported that global health strategies aim to ensure that 80% of individuals living with chronic hepatitis B and C receive treatment by 2030. Therefore, the rising prevalence of HBV infection is supporting the growth of the engerix-B market.
Rising travel and migration are also expected to propel the growth of the engerix-B market. Travel and migration involve people moving across regions or countries for reasons such as leisure, work, education, family reunification, or environmental factors. These movements increase exposure to high-risk areas for HBV infection. Engerix-B provides essential protection for travelers and migrants by reducing the risk of infection through contaminated blood, needles, or bodily fluids, ensuring safer movement between regions. For instance, in May 2024, the Office for National Statistics reported that the UK recorded 38 million visits in 2023, an increase of 6.7 million compared to 2022, while outbound trips by UK residents rose from 71 million in 2022 to 86.2 million in 2023. Consequently, increasing travel and migration are driving the growth of the engerix-B market.
Rising healthcare expenditure is another key factor supporting the growth of the engerix-B market. Healthcare expenditure encompasses all spending on medical services, treatments, and products across both public and private sectors. Factors such as an aging population and higher prevalence of chronic and age-related conditions contribute to increased healthcare costs. Greater healthcare spending enhances the accessibility of vaccines like Engerix-B by funding vaccination programs, strengthening healthcare infrastructure, and ensuring affordability, which reduces long-term costs associated with treating hepatitis B and its complications. For example, in May 2024, the Office for National Statistics reported that total healthcare expenditure in the UK increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is expected to drive the growth of the engerix-B market.
Major companies operating in the engerix-b market are GlaxoSmithKline plc.
North America was the largest region in the engerix-B market in 2025. The regions covered in the engerix-b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the engerix-b market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the engerix-b market by affecting vaccine raw material sourcing, packaging components, and international distribution logistics. These impacts are most visible in public vaccination programs and healthcare institutions in regions dependent on imported vaccines. Increased costs may strain government procurement budgets and slow rollout schedules. However, tariffs are also encouraging domestic vaccine manufacturing and regional production hubs. This supports long term vaccine supply security and self sufficiency.
The engerix-b market research report is one of a series of new reports that provides engerix-b market statistics, including engerix-b industry global market size, regional shares, competitors with a engerix-b market share, detailed engerix-b market segments, market trends and opportunities, and any further data you may need to thrive in the engerix-b industry. This engerix-b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Engerix-B is a vaccine that protects against hepatitis B, a serious liver infection caused by the hepatitis B virus (HBV). It contains hepatitis B surface antigen (HBsAg), a viral protein that stimulates the immune system to produce antibodies without causing the disease.
The primary indications for Engerix-B include prevention of hepatitis B virus (HBV) infection, chronic hepatitis B prevention, protection for healthcare workers and high-risk populations, and post-exposure prophylaxis. The vaccine works by triggering the immune system to generate antibodies, providing long-term immunity for at-risk individuals. It is distributed through hospitals, clinics, vaccination centers, and pharmacies, and is used by private healthcare providers, long-term care facilities, and educational institutions.
The engerix-B market consists of sales of adjuvants, buffering agents, and excipients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Engerix-B Market Characteristics
3. Engerix-B Market Supply Chain Analysis
4. Global Engerix-B Market Trends and Strategies
5. Engerix-B Market Analysis of End Use Industries
7. Global Engerix-B Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Engerix-B Total Addressable Market (TAM) Analysis for the Market
9. Engerix-B Market Segmentation
10. Engerix-B Market Regional and Country Analysis
11. Asia-Pacific Engerix-B Market
12. China Engerix-B Market
13. India Engerix-B Market
14. Japan Engerix-B Market
15. Australia Engerix-B Market
16. South Korea Engerix-B Market
17. Western Europe Engerix-B Market
18. UK Engerix-B Market
19. Germany Engerix-B Market
20. France Engerix-B Market
21. Eastern Europe Engerix-B Market
22. North America Engerix-B Market
23. USA Engerix-B Market
24. Canada Engerix-B Market
25. South America Engerix-B Market
26. Middle East Engerix-B Market
27. Africa Engerix-B Market
29. Engerix-B Market Competitive Landscape and Company Profiles
32. Engerix-B Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Engerix-B Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses engerix-b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for engerix-b? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The engerix-b market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Prevention Of Hepatitis B Virus (HBV) Infection; Chronic Hepatitis B Prevention; Healthcare Workers And High-Risk Populations; Post-Exposure Prophylaxis2) By Distribution Channel: Hospitals; Clinics; Vaccination Centers; Pharmacies
3) By End-Use: Private Healthcare Providers; Long-Term Care Facilities; Educational Institutions
Companies Mentioned: GlaxoSmithKline plc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Engerix-B market report include:- GlaxoSmithKline plc.
